Treatment of pituitary-dependent cushings disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial
However, understanding your baseline receptor sensitivity and metabolic risk variants can support a more informed, personalized discussion with your provider about which starting approach makes sense for you
Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A
Yes, you'll likely experience residual appetite suppression for 24 weeks after your final injection as the drug gradually leaves your system
It is often used to support: Energy and vitality Sleep quality Immune function Muscle tone and healthy body composition Sermorelin can be an option for patients seeking age-management support without direct hormone replacement